DuoBody-FAPαxDR4 Is a Novel DR4 Agonist that Induces Potent Antitumor Activity through FAPα-Dependent, DR4 Transactivation–Mediated Apoptosis
Purpose Death receptor (DR) agonism is a promising strategy for cancer treatment, but clinical success has been limited by insufficient efficacy and/or on-target off-tumor toxicity, particularly hepatotoxicity. We hypothesized that restricting DR4 activation to the tumor microenvironment may enhance both therapeutic efficacy and safety. Fibroblast activation protein alpha (FAPα) is overexpressed on cancer-associated fibroblasts (CAFs) within the tumor stroma of several solid cancers, making it an attractive target for conditional activation of DR4 on tumor cells. Experimental Design DuoBody-FAPαxDR4 is an Fc-silenced IgG1 bispecific antibody that binds to DR4 on tumor cells and FAPα on CAFs. Functional activity of DuoBody-FAPαxDR4 was assessed in tumor cell lines and colorectal carcinoma (CRC) patient-derived organoids (PDOs) using viability and bioluminescent reporter assays. Toxicity was tested using human primary liver spheroids in vitro. In vivo, antitumor activity was evaluated in patient-derived xenograft (PDX) models and models for spontaneous multiorgan metastasis by implantation of CRC-derived organoids into the cecum. Results DuoBody-FAPαxDR4 localized to the fibroblast-tumor cell interface, where it induced conditional caspase-8 activation and cytotoxicity in DR4-expressing tumor cells while sparing the fibroblasts. DuoBody-FAPαxDR4 did not induce cytotoxicity in human primary liver spheroids. In vivo, DuoBody-FAPαxDR4 demonstrated potent antitumor activity in PDX models and in mouse models of multiorgan metastases of CRC. Conclusions DuoBody-FAPαxDR4 is a novel bispecific antibody that conditionally activates DR4 on cancer cells exclusively in the presence of FAPα-expressing cells, resulting in targeted apoptosis and antitumor activity. These findings supported the initiation of a first-in-human trial in patients with solid tumors.
Authors
- Esther C.W. Breij (ORCID: https://orcid.org/0000-0002-5368-6849)
- Onno Kranenburg (ORCID: https://orcid.org/0000-0002-2112-4390)
- Edo Elstak (ORCID: https://orcid.org/0000-0003-2484-6601)
- Theo S. Plantinga (ORCID: https://orcid.org/0000-0003-4990-6084)
- Saskia D. van Asten (ORCID: https://orcid.org/0000-0001-6498-1176)
- Susanne van Schelven (ORCID: https://orcid.org/0000-0002-4233-0847)
- Monique Luijten (ORCID: https://orcid.org/0000-0002-1103-5204)
- Marije B. Overdijk (ORCID: https://orcid.org/0009-0006-5295-2339)
- Madelon Paauwe (ORCID: https://orcid.org/0000-0002-8204-0027)
- André Verheem (ORCID: https://orcid.org/0009-0004-1703-4992)
- Ilse Jongerius (ORCID: https://orcid.org/0000-0002-7759-9897)
- Anne van de Loo (ORCID: https://orcid.org/0009-0008-2767-5637)
- Bart E.C.G. de Goeij (ORCID: https://orcid.org/0000-0002-8093-238X)
- Jamila Laoukili (ORCID: https://orcid.org/0009-0001-8867-2375)
- Grietje Andringa (ORCID: https://orcid.org/0009-0009-7628-2730)
- Edouard Souteyrand (ORCID: https://orcid.org/0009-0007-5087-1719)
- David P. E. Satijn (ORCID: https://orcid.org/0009-0006-2026-3360)
Institutions
- Utrecht University (NL)
- University Medical Center Utrecht (NL)
- Genmab (Netherlands) (NL)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-0600
- Primary Topic
- Cell death mechanisms and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00